Monitor for upcoming preclinical study initiation in Q2 2026 and any subsequent FDA feedback; clinical trial commencement later in 2026 could serve as a near-term catalyst for investor interest.
Price Chart
Executive Summary
Polyrizon Ltd. announced a strategic agreement with a leading global preclinical CRO to conduct ISO 10993-compliant biocompatibility studies, a key step toward initiating clinical trials later in 2026. This follows recent progress including GMP manufacturing and a successful FDA pre-submission meeting, advancing its intranasal hydrogel platform for allergen and virus protection.
Key Facts
- Polyrizon signed an agreement with a global preclinical CRO to conduct GLP-compliant, ISO 10993 biocompatibility studies.
- Studies include cytotoxicity, sensitization, intracutaneous reactivity, acute systemic toxicity, and pyrogenicity assessments.
- Preclinical work is expected to begin in Q2 2026, supporting a planned clinical trial initiation later this year.
- Recent milestones include GMP manufacturing of clinical trial material and a successful FDA pre-submission meeting.
- The company remains in pre-clinical development with no revenue-generating products or commercial operations.
Financial Impact
No direct financial impact disclosed; costs associated with preclinical studies are expected to be immaterial relative to cash runway.
Risk Factors
- Failure to complete preclinical studies on time or with favorable results could delay clinical trials.
- As a pre-revenue biotech, Polyrizon remains dependent on future financing, exposing it to dilution risk.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3257164 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 6-K | $9.01 | awaiting T+1 | — | $8.96 (−0.59%) |
Oct 27, 2026 today | Press Release | $9.01 | awaiting T+1 | — | $8.96 (−0.59%) |
Oct 5, 2026 21d ago | 6-K | $9.67 $9.15 | ▼ −5.37% | ▼ −5.13% | $8.96 (−7.37%) |
Oct 2, 2026 25d ago | EFFECT | $9.61 $9.26 | ▲ +3.64% | ▲ +4.32% | $8.96 (+6.80%) |
Sep 22, 2026 5w ago | Press Release | $10.66 $11.16 | ▲ +4.69% | ▲ +5.41% | $8.96 (−15.98%) |
Sep 18, 2026 5w ago | F-1 | $10.90 $10.66 | ▲ +2.20% | ▲ +2.19% | $8.96 (+17.83%) |
Sep 4, 2026 7w ago | Press Release | $11.24 $11.15 | ▲ +0.80% | ▲ +0.25% | $8.96 (+20.31%) |
Sep 4, 2026 7w ago | 6-K | $11.24 $11.15 | ▲ +0.80% | ▲ +0.25% | $8.96 (+20.31%) |
Sep 4, 2026 7w ago | 424B5 | $11.24 $11.15 | ▲ +0.80% | ▲ +0.25% | $8.96 (+20.31%) |
Aug 20, 2026 9w ago | 6-K | $10.30 $10.70 | ▲ +3.88% | ▲ +4.18% | $8.96 (−13.04%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers